5 completed, 4 recruiting, 1 not yet recruiting, 1 terminated. 11 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 5, Recruiting 4, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Margins of Excision: new trials by email Literature Review of Margins of Excision trials Research Report on Margins of Excision
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing Timolol 0.5% Ophthalmic Solution, Hydrogel of placebo - Mohs Micrographic Surgery, Excision Margin | Phase 2 | Not yet recruiting | University of California, Davis | 220 | 2026-10-01 | 2026-08-18 |
| Defining the Ablative Dose for Y-90 TARE Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Northwestern University | 30 | 2026-05-15 | 2026-09-15 |
| Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors Indocyanine Green (ICG) - Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Margin Assessment | Phase 2 | Recruiting | Medical University of South Carolina | 30 | 2026-05-04 | 2026-07-07 |
| Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV - Brain Metastases, Adult, Brain Tumor - Metastatic | Phase 2 | Recruiting | Ayal A. Aizer, MD | 60 | 2025-12-30 | 2026-09-08 |
| Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy NeuroSAFE procedure, LaserSAFE procedure - Prostate Cancer | Phase 1 / Phase 2 | Completed | University College, London | 21 | 2024-05-15 | 2025-01-10 |
| B7-H3 NIR Imaging for Osteosarcoma Surgery a targeted probe B7H3-IRDye800CW - Osteosarcoma, Resection Margins | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 32 | 2024-01-01 | 2025-01-16 |
| Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer Simvastatin 40mg, Placebo oral capsule - Breast Cancer, Chemotherapy Effect | Phase 2 | Completed | Universitas Indonesia | 60 | 2018-01-15 | 2020-06-05 |
| A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer TORS, Adjuvant Radiation Therapy - Oropharyngeal Cancer | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 60 | 2014-02-01 | 2019-11-21 |
| Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy Indocyanine Green - Breast Cancer | Phase 2 | Completed | Jules Bordet Institute | 20 | 2014-01-01 | 2023-12-15 |
| Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer Sunitinib, Everolimus - Metastatic Renal Cell Carcinoma | Phase 2 | Terminated | Associació per a la Recerca Oncologica, Spain | 41 | 2013-02-12 | 2017-10-02 |
| Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer RAD001(everolimus), interferon alfa-2a, bevacizumab - Carcinoma, Adenocarcinoma | Phase 2 | Completed | Novartis Pharmaceuticals | 365 | 2008-11-12 | 2017-03-20 |
Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Neoplasms (2) · Adenocarcinoma (1) · Brain Neoplasms (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Fasting (1) · Head and Neck Neoplasms (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Oropharyngeal Neoplasms (1) · Osteosarcoma (1) · Prostatic Neoplasms (1)
Morphological and Microscopic Findings (11) · Pathological Conditions, Signs and Symptoms (11) · Neoplasms by Site (9) · Neoplasms (8) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (4) · Carcinoma (3) · Male Urogenital Diseases (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Adenocarcinoma (2) · Breast Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2)
Everolimus (2) · Indocyanine Green (2) · Bevacizumab (1) · Interferon alpha-2 (1) · Ophthalmic Solutions (1) · Simvastatin (1) · Sunitinib (1) · Timolol (1)
Abramson Cancer Center at Penn Medicine (1) · Associació per a la Recerca Oncologica, Spain (1) · Ayal A. Aizer, MD (1) · Jules Bordet Institute (1) · Medical University of South Carolina (1) · Northwestern University (1) · Novartis Pharmaceuticals (1) · Peking University People's Hospital (1) · Universitas Indonesia (1) · University College, London (1) · University of California, Davis (1)
United States (6) · Belgium (2) · France (2) · Spain (2) · United Kingdom (2) · Brazil (1) · China (1) · Czechia (1) · Egypt (1) · Germany (1) · Greece (1) · Hong Kong (1) · Hungary (1) · Indonesia (1) · Italy (1)
Alexander Lin, MD (1) · Ayal A Aizer, MD, MHS (1) · Baju Adji (1) · Filipus Dasawala, MD (1) · Greg Shaw (1) · Hanifah Hasan, MD (1) · Jason Newman, MD, FACS (1) · Joaquim Bellmunt, MD/PhD (1) · Muhammad Rizki Kamil, MD (1) · Nurjati Chairani Siregar, MD (1)
PMID 25851632, PMID 31785337, PMID 32654362, PMID 37146227, PMID 38502871, PMID 41309506
2008 (1)